Compare Fidelity National Information Servcs Inc (FIS) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fidelity National Information Servcs Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Fidelity National Information Servcs Inc trades at $34.36 (market cap $17.44B), while Regeneron Pharmaceuticals Inc trades at $737.72 (market cap $76.40B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 4.4× Fidelity National Information Servcs Inc's market cap, and Fidelity National Information Servcs Inc pays the higher dividend (5.2%). Which is the better fit depends on your goals — on Pluang, investors hold Fidelity National Information Servcs Inc for 88 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| FIS | REGN | |
|---|---|---|
Market Cap | $17.44B | $76.40B |
Volume | 6,437,765 | 626,381 |
Sector | Technology | Health |
52-Week High | $68.57 | $852.03 |
52-Week Low | $32.44 | $557.73 |
Typical Hold Time | 88 Days | 107 Days |
Enterprise Value | $37.95B | $71.12B |
Dividend Yield | 5.2% | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIS trades at $34.34, up 2.75% today, with a bearish technical signal despite recent earnings beats in Q1 and Q2 2026. The company shows improving fundamentals with revenue growth from $10.7B in 2025 to projected $12.2B in 2026 and strong profitability metrics including 27.65% net income margin. Recent news highlights strategic wins in core banking modernization and embedded finance platforms.
The stock presents a compelling value opportunity with a low P/E of 5.2 and analyst consensus target of $47.54 (38% upside), though risks include significant debt load and volatile cash flow trends. Institutional sentiment remains positive with 57% buy ratings, but technical weakness near key support at $33 requires monitoring.
Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.
The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
